GleamWall
中文EN

DNLI Denali Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1714899 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY37.0%
TTM EPS YoY41.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.9%
ROA-27.2%
ROIC (approx.)-50.8%
Asset turnover—

Leverage & solvency

Liabilities / assets26.2%
Debt / equity0.00x
Current ratio6.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.41x
Accruals ratio11.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$17.78M$3.60M—$0$0$0—$0
Cost of revenue$192,000$93,000——$0$0——
Gross profit$17.59M$3.51M——$0$0——
R&D expense$106.10M$97.02M$103.85M$97.91M$101.95M$102.70M$116.23M$99.79M
SG&A expense$37.48M$36.28M$33.51M$39.46M$35.48M$32.27M$29.35M$30.06M
Operating income-$126.75M-$130.54M-$137.36M-$137.37M-$137.43M-$134.96M-$145.58M-$129.85M
Net income$70.13M-$127.55M-$128.45M-$128.55M-$126.90M-$124.12M-$132.97M-$114.75M
EBITDA-$123.18M-$126.97M-$134.51M-$134.50M-$134.49M-$131.92M-$143.25M-$127.99M
EPS (basic)0.37-0.68-0.69—-0.74-0.72-0.78—
EPS (diluted)0.37-0.68-0.69—-0.74-0.72-0.78—
Weighted avg. shares (diluted)192.08M187.31M186.64M—172.42M171.45M171.22M—
Balance sheet
Cash & equivalents$102.87M$201.53M$387.63M$205.33M$94.07M$144.31M$60.05M$176.53M
Short-term investments$413.33M$508.94M$600.06M$662.55M$757.24M$757.75M$760.98M$657.37M
Receivables$18.88M$3.93M—$0————
Inventory$26.27M$4.14M—$0————
Current assets$591.71M$753.93M$1.02B$900.66M$882.60M$934.71M$878.64M$864.44M
PP&E, net$47.91M$49.93M$51.73M$52.40M$53.73M$58.72M$57.77M$55.24M
Intangibles$34.50M$35.25M$36.00M$0————
Total assets$1.26B$1.16B$1.27B$1.14B$1.06B$1.17B$1.27B$1.37B
Current liabilities$95.26M$90.08M$110.16M$98.35M$90.15M$91.06M$91.88M$102.21M
Total liabilities$329.65M$322.78M$339.93M$131.09M$129.42M$139.19M$148.66M$144.50M
Shareholders' equity$926.39M$835.18M$926.10M$1.01B$926.20M$1.03B$1.12B$1.23B
Shares outstanding160.26M159.76M158.66M156.18M146.63M145.69M145.25M144.22M
Cash flow statement
Operating cash flow-$117.44M-$97.00M-$131.20M-$98.54M-$107.30M-$75.30M-$131.47M-$83.72M
Capital expenditure$1.01M$805,000$2.47M$1.52M-$1.38M$4.28M$5.08M$5.09M
Free cash flow-$118.45M-$97.81M-$133.67M-$100.06M-$105.92M-$79.58M-$136.55M-$88.81M
Investing cash flow$16.19M-$104.08M$94.46M$20.77M$57.83M$157.94M$18.75M$172.21M
Financing cash flow$2.59M$14.98M$219.04M$192.13M-$778,000$1.62M-$3.76M-$4.17M
Depreciation & amortization$3.58M$3.57M$2.85M$2.87M$2.95M$3.04M$2.33M$1.85M
Stock-based compensation$22.86M$22.91M$23.09M$23.95M$25.14M$25.39M$25.16M$25.08M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.